Potential Protein Markers for Breast Cancer Recurrence: a Retrospective Cohort Study

Overview

Journal Cancer Causes Control

Specialties Oncology
Public Health

Date 2018 Nov 30

PMID 30488343

Citations 2

Authors

Chunyan He

Rina Plattner

Vivek Rangnekar

Binhua Zhou

Chunming Liu

Rachel L Stewart

Bin Huang

Chi Wang

Thomas C Tucker

Affiliations

Soon will be listed here.

Abstract

Background: We evaluated five key proteins involved in various cancer-related pathways and assessed their relation to breast cancer recurrence.

Methods: We used the Kentucky Cancer Registry to retrospectively identify primary invasive breast cancer cases (n = 475) that were diagnosed and treated at University of Kentucky Medical Center between 2000 and 2007. Breast cancer recurrence was observed in 62 cases during the 5-year follow-up after diagnosis. Protein expression or activity level was analyzed from surgery tissue using immuno-histochemical assays.

Results: Compared to ER+/PR+/HER2- patients without recurrence, those with recurrence had higher TWIST expression (p = 0.049) but lower ABL1/ABL2 activity (p = 0.003) in primary tumors. We also found that triple-negative breast cancer patients with recurrence had higher SNAI1 expression compared to those without recurrence (p = 0.03). After adjusting for potential confounders, the higher ABL1/ABL2 activity in primary tumors was associated with a decreased risk of recurrence (OR 0.72, 95% CI 0.85-0.90) among ER+/PR+/HER2- patients. In addition, among patients with recurrence we observed that the activity level of ABL1/ABL2 was significantly increased in recurrent tumors compared to the matched primary tumors regardless of the subtype (p = 0.013).

Conclusions: These findings provide evidence that the expression/activity level of various proteins may be differentially associated with risk of recurrence of breast tumor subtypes.

Citing Articles

Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells.

Sauer S, Reed D, Ihnat M, Hurst R, Warshawsky D, Barkan D Front Oncol. 2021; 11:659963.

PMID: 33987095 PMC: 8111294. DOI: 10.3389/fonc.2021.659963.

EnABLing Tumor Growth and Progression: Recent progress in unraveling the functions of ABL kinases in solid tumor cells.

Tripathi R, Liu Z, Plattner R Curr Pharmacol Rep. 2019; 4(5):367-379.

PMID: 30746323 PMC: 6368175. DOI: 10.1007/s40495-018-0149-y.

References

Harvey J, Clark G, Osborne C, Allred D . Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999; 17(5):1474-81. DOI: 10.1200/JCO.1999.17.5.1474. View

Hanahan D, Weinberg R . The hallmarks of cancer. Cell. 2000; 100(1):57-70. DOI: 10.1016/s0092-8674(00)81683-9. View

Rhodes J, York R, Tara D, Tajinda K, Druker B . CrkL functions as a nuclear adaptor and transcriptional activator in Bcr-Abl-expressing cells. Exp Hematol. 2000; 28(3):305-10. DOI: 10.1016/s0301-472x(99)00148-4. View

Druker B, Talpaz M, Resta D, Peng B, Buchdunger E, Ford J . Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344(14):1031-7. DOI: 10.1056/NEJM200104053441401. View

Liu C, Li Y, Semenov M, Han C, Baeg G, Tan Y . Control of beta-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell. 2002; 108(6):837-47. DOI: 10.1016/s0092-8674(02)00685-2. View

Blanco M, Moreno-Bueno G, Sarrio D, Locascio A, Cano A, Palacios J . Correlation of Snail expression with histological grade and lymph node status in breast carcinomas. Oncogene. 2002; 21(20):3241-6. DOI: 10.1038/sj.onc.1205416. View

Thiery J . Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002; 2(6):442-54. DOI: 10.1038/nrc822. View

van de Vijver M, He Y, Vant Veer L, Dai H, Hart A, Voskuil D . A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002; 347(25):1999-2009. DOI: 10.1056/NEJMoa021967. View

Yang J, Mani S, Liu Donaher J, Ramaswamy S, Itzykson R, Come C . Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis. Cell. 2004; 117(7):927-39. DOI: 10.1016/j.cell.2004.06.006. View

10.

Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M . A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med. 2004; 351(27):2817-26. DOI: 10.1056/NEJMoa041588. View

11.

Collins L, Botero M, Schnitt S . Bimodal frequency distribution of estrogen receptor immunohistochemical staining results in breast cancer: an analysis of 825 cases. Am J Clin Pathol. 2005; 123(1):16-20. DOI: 10.1309/hcf035n9wk40etj0. View

12.

Hockel M, Dornhofer N . The hydra phenomenon of cancer: why tumors recur locally after microscopically complete resection. Cancer Res. 2005; 65(8):2997-3002. DOI: 10.1158/0008-5472.CAN-04-3868. View

13.

Martin T, Goyal A, Watkins G, Jiang W . Expression of the transcription factors snail, slug, and twist and their clinical significance in human breast cancer. Ann Surg Oncol. 2005; 12(6):488-96. DOI: 10.1245/ASO.2005.04.010. View

14.

. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 365(9472):1687-717. DOI: 10.1016/S0140-6736(05)66544-0. View

15.

Moody S, Perez D, Pan T, Sarkisian C, Portocarrero C, Sterner C . The transcriptional repressor Snail promotes mammary tumor recurrence. Cancer Cell. 2005; 8(3):197-209. DOI: 10.1016/j.ccr.2005.07.009. View

16.

Buyse M, Loi S, Veer L, Viale G, Delorenzi M, Glas A . Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J Natl Cancer Inst. 2006; 98(17):1183-92. DOI: 10.1093/jnci/djj329. View

17.

Paulson K, Rieger-Christ K, McDevitt M, Kuperwasser C, Kim J, Unanue V . Alterations of the HBP1 transcriptional repressor are associated with invasive breast cancer. Cancer Res. 2007; 67(13):6136-45. DOI: 10.1158/0008-5472.CAN-07-0567. View

18.

Srinivasan D, Sims J, Plattner R . Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene. 2007; 27(8):1095-105. DOI: 10.1038/sj.onc.1210714. View

19.

Kar B, Reichman C, Singh S, OConnor J, Birge R . Proapoptotic function of the nuclear Crk II adaptor protein. Biochemistry. 2007; 46(38):10828-40. DOI: 10.1021/bi700537e. View

20.

Debies M, Gestl S, Mathers J, Mikse O, Leonard T, Moody S . Tumor escape in a Wnt1-dependent mouse breast cancer model is enabled by p19Arf/p53 pathway lesions but not p16 Ink4a loss. J Clin Invest. 2007; 118(1):51-63. PMC: 2104482. DOI: 10.1172/JCI33320. View